Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q92871
UPID:
PMM1_HUMAN
Alternative names:
PMMH-22
Alternative UPACC:
Q92871; A8K003; Q92586
Background:
Phosphomannomutase 1 (PMM1), also known by its alternative name PMMH-22, plays a pivotal role in cellular processes by being involved in the synthesis of GDP-mannose and dolichol-phosphate-mannose. These compounds are essential for numerous mannosyl transfer reactions. Additionally, PMM1 may have a role in the degradation of glucose-1,6-bisphosphate in ischemic brain conditions, highlighting its importance in metabolic pathways.
Therapeutic significance:
Understanding the role of Phosphomannomutase 1 could open doors to potential therapeutic strategies. Its involvement in critical biochemical pathways suggests that targeting PMM1 could offer new avenues for treating metabolic disorders or managing ischemic brain injuries.